EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Novel insights into antithrombin deficiency enabled by mass spectrometry-based precision diagnostics

Mirjam Kruijt, Maria Eugenia de la Morena-Barrio, Javier Corral, Christa M Cobbaert, L Renee Ruhaak

Journal of Thrombosis and Haemostasis · 2025

DOI: 10.1016/j.jtha.2024.10.005 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Thrombosis and Haemostasis, 2025. Verfasst von Mirjam Kruijt und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Chemistry and Laboratory Medicine, Leiden University Medical Center, Leiden, the Netherlands. Hauptthemen laut MEDLINE: Antithrombin III Deficiency, Mass Spectrometry, Antithrombin III, Precision Medicine. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Fundación Séneca, Horizon 2020, H2020 Marie Skłodowska-Curie Actions.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Although P5 (preventive, personalized, predictive, participatory, psychocognitive) medicine and patient-focused healthcare are gaining ground in various healthcare areas, the diagnosis of antithrombin deficiency (ATD) is still based on crude diagnostic tests, clustering patients into clinically heterogeneous subgroups whereby relevant thrombophilia phenotypes may go unnoticed. Clinical pathways and the majority of evidence are based on these tests; therefore, generic treatment is still the norm. OBJECTIVES: To unravel the heterogeneity of ATD, a mass spectrometry (liquid chromatography coupled to multiple-reaction-monitoring mass spectrometry [LC-MRM-MS])-based test for antithrombin was developed allowing molecular characterization of the antithrombin proteoforms in patient plasma. This study provides the first insight into the tests' clinical performance. METHODS: Plasma from 91 unrelated ATD patients and 41 patients with a congenital disorder of glycosylation affecting antithrombin glycosylation were characterized functionally, genetically, and analyzed by LC-MRM-MS. An established data analysis strategy was applied for quantitation and molecular characterization of antithrombin proteoforms. RESULTS: The test recognized patients with a quantitative defect, discriminated between type I and type II ATD, and identified variant proteoforms. Overall, the diagnostic sensitivity for ATD was 100% for LC-MRM-MS compared with 81.1% by the functional test. Type II ATD, a subtype prone to misdiagnosis, revealed an even larger difference of 100% identification by LC-MRM-MS vs 56.8% by functional test. CONCLUSION: The qualitative and quantitative mass spectrometry-based AT-test can serve as a platform for investigating the molecular basis of the clinical heterogeneity of ATD. This "precision diagnostics" approach for ATD can lower diagnostic uncertainty and modernize the ATD diagnostic and clinical pathways.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antithrombin III DeficiencyMass SpectrometryAntithrombin IIIPrecision MedicineHumansChromatography, LiquidFemaleMaleGlycosylationAdultMiddle AgedPhenotypeAntithrombinsBiomarkersPredictive Value of Tests

Stichwörter der Autor:innen

hereditary antithrombin deficiencymass spectrometrymolecular testingprotein isoforms

Substanzen

Antithrombin IIIAntithrombinsBiomarkers

Autor:innen und Institutionen

  • Department of Clinical Chemistry and Laboratory Medicine, Leiden University Medical Center, Leiden, the Netherlands.
  • Servicio de Hematología, Hospital Universitario Morales Meseguer, Centro Regional de Hemodonación, Universidad de Murcia, IMIB-Pascual Parrilla, CIBERER-ISCIII, Murcia, Spain.
  • Department of Clinical Chemistry and Laboratory Medicine, Leiden University Medical Center, Leiden, the Netherlands. Electronic address: l.r.ruhaak@lumc.nl.

Förderung

  • Fundación Séneca
  • Horizon 2020
  • H2020 Marie Skłodowska-Curie Actions
  • Horizon 2020 Framework Programme
  • European Commission
  • Instituto de Salud Carlos III
  • España Ministerio de Ciencia e Innovación

Zitieren

APA

Kruijt, M., de la Morena-Barrio, M. E., Corral, J., Cobbaert, C. M., & Ruhaak, L. R. (2025). Novel insights into antithrombin deficiency enabled by mass spectrometry-based precision diagnostics. Journal of Thrombosis and Haemostasis. https://doi.org/10.1016/j.jtha.2024.10.005

Vancouver

Kruijt M, de la Morena-Barrio ME, Corral J, Cobbaert CM, Ruhaak LR. Novel insights into antithrombin deficiency enabled by mass spectrometry-based precision diagnostics. Journal of Thrombosis and Haemostasis. 2025. doi:10.1016/j.jtha.2024.10.005

BibTeX
@article{Kruijt2025,
  author = {Kruijt, Mirjam and de la Morena-Barrio, Maria Eugenia and Corral, Javier and Cobbaert, Christa M and Ruhaak, L Renee},
  title = {Novel insights into antithrombin deficiency enabled by mass spectrometry-based precision diagnostics},
  journal = {Journal of Thrombosis and Haemostasis},
  year = {2025},
  doi = {10.1016/j.jtha.2024.10.005}
}
Kostenlos starten →